New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
08:01 EDTGALTGalectin Therapeutics presents preclinical data on GR-MD-02
Galectin Therapeutics presented new preclinical data on the mechanism of action of GR-MD-02 at the American Association for the Study of Liver Disease Annual Meeting in Boston, MA. GR-MD-02 is the Company’s lead galectin inhibitor in development for the treatment of non-alcoholic steatohepatitis, or fatty liver disease. These new data help to further explain the mechanism of action of GR-MD-02, showing that this galectin inhibitor affects multiple pathways involved with both the prevention and reversal of fibrosis in NASH pathology. The new data show that Galectin-3 protein expression was markedly increased in animals with NASH, and those levels were dramatically reduced to barely detectable levels following treatment with GR-MD-02. Elevated expression of iNOS, an important inflammatory mediator, and CD36, a scavenger receptor involved in the pathogenesis of NASH, were markedly reduced following treatment with GR-MD-02.
News For GALT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
07:49 EDTGALTGalectin Therapeutics initiates enrollment for GR-MD-02 Phase 2 clinical trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use